ACUTECT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ACUTECT (ACUTECT).
ACUTECT is a diagnostic radiopharmaceutical that contains technetium-99m bound to a peptide that binds to the glycoprotein IIb/IIIa receptors on activated platelets, allowing imaging of acute venous thrombosis.
| Metabolism | The radiopharmaceutical undergoes renal excretion; the peptide component is metabolized via proteolysis. |
| Excretion | Primarily renal elimination: ~95% of the injected dose is excreted unchanged in the urine within 24 hours. Less than 5% is eliminated via the biliary/fecal route. |
| Half-life | Terminal elimination half-life is approximately 6 hours for the initial distribution phase, with a prolonged terminal phase of 24-48 hours due to slow release from renal tubules. Clinical context: allows for delayed imaging up to 24 hours post-injection. |
| Protein binding | Approximately 50-60% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd ~0.3-0.4 L/kg, indicating distribution primarily in extracellular fluid and renal parenchyma. |
| Bioavailability | Not applicable (administered only via intravenous injection). |
| Onset of Action | Intravenous administration: target tissue visualization within 1 hour (e.g., renal cortex). Optimal imaging at 2-4 hours post-injection. |
| Duration of Action | Diagnostic imaging window: 2-24 hours post-injection. Adequate renal visualization persists for up to 24 hours, enabling delayed static imaging. |
For adult patients: 0.9 mg IV over 30 seconds every 12 hours for 5 days, initiated within 4 hours of symptom onset.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for GFR ≥ 30 mL/min. For GFR < 30 mL/min or on dialysis: 0.45 mg IV every 12 hours for 5 days. |
| Liver impairment | No dose adjustment required for Child-Pugh A or B. Not recommended in Child-Pugh C (no data). |
| Pediatric use | Not approved for use in pediatric patients (safety and efficacy not established). |
| Geriatric use | No specific dose adjustment; use with caution due to potential renal impairment. Monitor renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ACUTECT (ACUTECT).
| Breastfeeding | Technetium-99m is excreted in human milk. The effective half-life in breast milk is approximately 4-6 hours. M/P ratio not specifically reported. Interrupt breastfeeding for at least 12-24 hours after administration to minimize infant exposure. |
| Teratogenic Risk | ACUTECT (technetium Tc-99m exametazime) is a radiopharmaceutical. Radiation exposure from diagnostic doses is generally below the threshold for teratogenicity. However, fetal risk is dose-dependent; for first trimester, there is potential for stochastic effects (carcinogenesis, genetic defects) with cumulative radiation doses >50 mGy. For second and third trimesters, risk is lower but still present. Use only if clearly needed and consider reducing dose. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Known hypersensitivity to any component of ACUTECT","Pregnancy (unless benefit outweighs risk)","Lactation (discontinue breastfeeding temporarily after administration)"]
| Precautions | ["Risk of allergic reactions including anaphylaxis","Radiation exposure risk similar to other radiopharmaceuticals","Use caution in patients with renal impairment due to reduced clearance","Not recommended for patients with known hypersensitivity to any component"] |
| Food/Dietary | No specific food interactions. Maintain adequate hydration before and after the procedure. |
| Clinical Pearls |
Loading safety data…
| Fetal Monitoring | Monitor maternal vital signs during injection. No specific fetal monitoring required for diagnostic use. Assess maternal radiation exposure and ensure cumulative dose is within safe limits (e.g., <50 mGy to fetus). |
| Fertility Effects | Limited data. Radiation exposure from diagnostic doses is unlikely to significantly impair fertility. However, high cumulative doses may theoretically affect gonadal function. Use only when necessary in patients of reproductive potential. |
| Technetium Tc-99m apcitide (ACUTECT) binds to glycoprotein IIb/IIIa receptors on activated platelets, allowing scintigraphic detection of acute venous thrombosis. Optimal imaging occurs 1-3 hours post-injection. Repeat injection may be needed if imaging is delayed >12 hours. Sensitivity is reduced in patients on anticoagulation therapy (heparin, warfarin, DOACs) due to decreased active thrombus targeting. False positives can occur with superficial phlebitis, surgical site inflammation, or hematomas. |
| Patient Advice | This medication is a radioactive tracer used to detect blood clots in your legs or lungs. · You will receive an intravenous injection and then undergo imaging scans at 1-3 hours after injection. · Drink plenty of fluids before and after the procedure to help eliminate the radioactive material from your body. · Notify your doctor if you are pregnant, breastfeeding, or have a history of allergic reactions to any medications. · Inform your healthcare provider about all current medications, especially blood thinners (heparin, warfarin, apixaban, rivaroxaban). · The amount of radiation exposure is low and is considered safe for diagnostic imaging. |